{"schema_version":"secwatch.filing_event.v1","accession":"0001425450-23-000066","form_type":"8-K","ticker":"KIDS","cik":"0001425450","company_name":"ORTHOPEDIATRICS CORP","filed_at":"2023-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.817565+00:00","generated_at":"2026-06-16T04:50:09.471610+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"OrthoPediatrics Q1 rev $31.6M +35% YoY, raises FY23 guidance to $148-151M","bullets":["Revenue $31.6M (+35% YoY); net loss $6.8M ($0.30/sh) vs $9.1M ($0.47/sh) prior year.","Trauma & Deformity rev +42%, Scoliosis +18%, Sports Medicine/Other +22%.","FY23 revenue guidance raised to $148-151M (21-23% growth); adj. EBITDA reaffirmed $3-4M.","Gross margin 75% vs 79% due to non-recurring favorable purchase price variances.","Cash $109.2M, no debt drawn on $50M credit line."],"urls":{"canonical":"https://secwatch.observer/filing/0001425450-23-000066","json":"https://secwatch.observer/filing/0001425450-23-000066.json","markdown":"https://secwatch.observer/filing/0001425450-23-000066.md","text":"https://secwatch.observer/filing/0001425450-23-000066.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1425450/000142545023000066/0001425450-23-000066-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1425450/000142545023000066/kids-20230501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T04:50:09.471610+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"34cf8006f19f220da7cacdbefee36f4b3c14a6b0","claim":"ORTHOPEDIATRICS CORP reported the first quarter ended March 31, 2023 results: revenue $31.6 million, net income $6.8 million, EPS $0.30 per basic and diluted share. Guidance raised.","evidence_excerpt":"Total revenue for the first quarter of 2023 was $31.6 million, a 35% increase compared to $23.4 million for the same period last year. The increase in revenue in the first quarter of 2023 includes $4.8 million of revenue contribution from MD Ortho and Pega Medical. U.S. revenue for the first quarter of 2023 was $23.8 million, a 31% increase compared to $18.2 million for the same period last year, representing 75% of total revenue. The increase in revenue in the first quarter of 2023 was driven primarily by organic growth in Trauma and Deformity and Scoliosis products as well as the addition of MD Ortho and Pega Medical. International revenue for the first quarter of 2023 was $7.8 million, a 49% increase compared to $5.2 million for the same period last year, representing 25% of total revenue. Growth in the quarter was primarily driven by the addition of MD Ortho and Pega Medical as well as increased procedure volumes. Trauma and Deformity revenue for the first quarter of 2023 was $23.4","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1425450/000142545023000066/0001425450-23-000066-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$31.6 million"},{"label":"Net income","value":"$6.8 million"},{"label":"EPS","value":"$0.30 per basic and diluted share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}